Search results for "atherosclerotic plaque"

showing 3 items of 13 documents

Sténoses carotidiennes athéromateuses : causes fondamentales et conséquences cliniques

2014

The treatment of high-grade carotid stenosis is surgery combined with best medical treatment. We established since 2003, a prospective database including all patients hospitalized in our vascular surgery department for management of carotid stenosis. Since 2012, the clinical database was completed for the establishment of a biological database. We present here the method of setting up such a database, and the results of four original studies on the theme of "high-risk patient" for carotid surgery: the influence of renal function, of the delay between symptoms and surgery and of the contralateral carotid artery on outcome and the proposal of a prognostic score of intolerance to carotid clamp…

Renal failure[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAtherosclerotic plaquesOcclusion carotidienne controlatéraleEndarterectomyShuntCarotideDatabasePlaque athéromateuseInsuffisance rénale[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyBase de donnéesEndartériectomie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCarotid
researchProduct

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)

2011

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a calcium-independent phospholipase A2 that circulates in plasma in association with lipoprotein particles, whereas in atherosclerotic plaques it is co-localized with macrophages. Lp-PLA2 generates two proinflammatory mediators, lysophosphatidylcholine and oxidized nonesterified fatty acids, which play a role in the development of atherosclerotic lesions and formation of a necrotic core, leading to more vulnerable plaques. Epidemiologic studies demonstrate that increased circulating levels of Lp-PLA2 predict an increased risk of myocardial infarction, stroke and cardiovascular mortality. Furthermore, histologic examination of diseased hum…

RiskPathologymedicine.medical_specialtycoronary-artery-diseasecardiovascular-diseasePharmacologyatherosclerotic plaqueProinflammatory cytokinechemistry.chemical_compoundPhospholipase A2cardiovascular diseaseDarapladibOximesDrug DiscoveryHyperlipidemiamedicineHumansMyocardial infarctionPharmacologyClinical Trials as Topicbiologylow-density-lipoproteinLipoprotein-associated phospholipase A2risk-assessmentCardiovascular AgentsAtherosclerosismedicine.diseaselp-pla2heart-diseaselipoproteinsLysophosphatidylcholinechemistryCardiovascular DiseasesinflammationBenzaldehydes1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteindarapladibrheumatoid-arthritislipids (amino acids peptides and proteins)atherosclerosisfactor-acetylhydrolase activityAtherosclerosis Cardiovascular disease Darapladib Inflammation Lipoproteins Lp-PLA2.platelet-activating-factorsecondary preventionLipoprotein
researchProduct

Peroxisome Proliferator-Activated Receptors and Atherosclerosis

2011

The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPARα, -γ, and -δ/β, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, …

peroxisome proliferator-activated receptors gammaPeroxisome proliferator-activated receptor gammamedicine.medical_specialtyPeroxisome Proliferator-Activated Receptorsperoxisome proliferator-activated receptors alphaInflammationatherosclerotic plaque030204 cardiovascular system & hematology03 medical and health sciencesatherosclerosi0302 clinical medicineInternal medicineHumansMedicineReceptorHypolipidemic Agents030304 developmental biology0303 health sciencesbusiness.industryFibric Acidsperoxisome proliferator-activated receptors γLipid metabolismPeroxisomeAtherosclerosisLipid Metabolismperoxisome proliferator-activated receptors α3. Good healthEndocrinologyNuclear receptorCancer researchlipids (amino acids peptides and proteins)Peroxisome proliferator-activated receptor alphaatherosclerosismedicine.symptomSignal transductionCardiology and Cardiovascular MedicinebusinessSignal TransductionAngiology
researchProduct